Carolina Urologic Research Center, LLC

Myrtle Beach, South Carolina 29572

12 studies enrolling now · 21 studies all time

What they study most

Advanced Renal Cell Carcinoma, Advanced Renal Cell Carcinoma (RCC), Advanced or Metastatic Renal Cell Carcinoma, Biochemical Recurrence of Malignant Neoplasm of Prostate, Bladder Cancer, Cancer of the Bladder, Recurrent, Cancer of the Prostate, Carcinoma, Renal Cell, Carcinoma, Renal Cell Metastasis, Carcinoma, Renal Cell, Advanced, Clear Cell Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma

Studies at this site

• LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve — Recruiting now
• A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) — Recruiting now
• This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. — Recruiting now
• A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. — Recruiting now
• A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer — Recruiting now
• A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer — Recruiting now
• Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer — Recruiting now
• Study of HLD-0915 in Patients With Metastatic Prostate Cancer — Recruiting now
• A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer — Recruiting now
• Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer — Recruiting now
• Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC — Recruiting now
• Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T — Recruiting now
• Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC — Running, not enrolling
• A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX — Completed
• Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin — Running, not enrolling
• CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer — Running, not enrolling
• A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). — Running, not enrolling
• Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer — Completed
• A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer — Running, not enrolling
• Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer — Running, not enrolling
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer — Running, not enrolling